What is Praeventix?
Founded by Dr. Douglas Pippin following foundational research at Temple University, Praeventix operates at the intersection of neurobiology and pharmacology. The company is currently advancing its lead clinical candidate, PRA-523, a first-in-class neuromodulatory therapy designed to modulate specific pathways associated with pruritus and IBD. Beyond its primary focus, the organization is leveraging its expertise in 5-HT7 receptor modulation to explore therapeutic interventions for cocaine use disorder. By bridging the gap between academic discovery and pre-clinical development, Praeventix is establishing a robust intellectual property portfolio aimed at high-value therapeutic markets.
How much funding has Praeventix raised?
Praeventix has raised a total of $3.1M across 2 funding rounds:
Debt
$69K
Stock/Share Issuance
$3M
Debt (2021): $69K with participation from PPP
Stock/Share Issuance (2026): $3M, investors not publicly disclosed
Key Investors in Praeventix
Undisclosed Investor
An institutional participant providing strategic capital to support the advancement of early-stage neuromodulatory therapies.
PPP
Public-Private Partnership
Undisclosed Investor
A private investment group specializing in the development of first-in-class pharmaceutical candidates.
What's next for Praeventix?
The recent capital injection provides the necessary runway for Praeventix to transition its lead assets through critical pre-clinical milestones. Strategic priorities for the coming fiscal periods include the optimization of PRA-523 for human clinical trials and the expansion of its research into 5-HT7 modulators. As the company scales its operations, it will likely seek further partnerships or licensing agreements to validate its therapeutic candidates. The focus remains on de-risking the pipeline while maintaining a lean, research-intensive operational model that maximizes the potential for future pharmaceutical acquisition or long-term commercialization.
See full Praeventix company page
